Canadian guidelines for the development of antidementia therapies: a conceptual summary.
The magnitude of the problems faced by Canadian society as a result of an aging population has been identified. Perhaps the most important concern related to this greying of Canada is the increasing incidence of dementia and Alzheimer's disease. Therapeutic options for these disorders have been limited to date. Advances in biotechnology and molecular biology will offer novel approaches to treatment. These and the expansion of more traditional therapeutic avenues require guidelines with the aim of optimizing their development.
Mohr
E
E
Institute of Mental Health Research, University of Ottawa/Royal Ottawa Hospital, Ontario, Canada.
Feldman
H
H
Gauthier
S
S
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis; D002170:Canada; D003071:Cognition; D003704:Dementia / Q000628:therapy*; D017408:Guidelines as Topic; D006801:Humans; D008875:Middle Aged; D012307:Risk Factors; D015899:Tomography, Emission-Computed, Single-Photon